Human Serum Albumin Market Trends Supporting 7% CAGR Growth Through 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Human Serum Albumin Market Forecast: Value Set To Climb From $6.21 Billion To $8.15 Billion
The human serum albumin market size has experienced robust expansion in recent years. It is projected to increase from $5.79 billion in 2025 to $6.21 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. The market’s historical growth can be attributed to the limited availability of recombinant hsa, reliance on plasma-derived hsa, growing hospital and clinical demand, increasing use in diagnostic and therapeutic applications, and the adoption of standard injection solutions.
The human serum albumin market size is anticipated to experience robust expansion in the coming years. It is projected to reach $8.16 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This predicted growth is primarily driven by factors such as the advancements in yeast, bacterial, and plant-based recombinant hsa development, an increasing need for fatty acid-free formulations, the broadening scope of drug delivery and nutrition enhancement uses, greater investments in research laboratories, and increased procurement by hospitals and blood banks. Key trends anticipated during this period encompass a heightened demand for both plasma-derived and recombinant human serum albumin, an expanded application of hsa in volume expanders and drug delivery systems, the growing preference for lyophilized powder and injection solutions, wider use in hospital and research laboratory settings, and a particular emphasis on fatty acid-free and specialized hsa preparations.
Get A Free Sample Report With In-Depth Market Insights:
Human Serum Albumin Market Growth Backed By Core Demand Fundamentals
The human serum albumin market is anticipated to expand due to the rising occurrence of liver ailments. These conditions encompass a range of issues that compromise liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. A key contributor to the surge in liver diseases is the growing rate of obesity, with surplus abdominal fat often resulting in non-alcoholic fatty liver disease (NAFLD), which involves fat buildup, inflammation, and can potentially lead to liver failure. Human serum albumin offers therapeutic benefits for liver disease patients by restoring blood volume, mitigating fluid accumulation, safeguarding kidney function, and enhancing prognoses for complications like ascites and hepatorenal syndrome. As an illustration, a report issued by the Office for Health Improvement and Disparities, a UK-based government body, indicated in December 2024 that premature fatalities from alcoholic liver disease saw a 3.6% rise in 2023, totaling 5,984 cases, up from 5,776 in 2022. Consequently, the expanding incidence of liver diseases is a significant impetus behind the growth of the human serum albumin market.
Human Serum Albumin Market Segment Outlook: Which Categories Are Growing Fastest?
The human serum albumin market covered in this report is segmented –
1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin
2) By Formulation Type: Injection Solutions, Lyophilized Powder
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies
4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents
5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks
Subsegments:
1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin
2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin
Human Serum Albumin Market Growth Trends Reshaping The Competitive Landscape
Leading companies within the human serum albumin market are prioritizing the development of innovative solutions, such as animal-free recombinant excipients. This focus aims to bolster product safety, enhance scalability, and ensure compliance with regulatory standards across biomanufacturing applications. An animal-free recombinant excipient is defined as a biologically engineered inactive substance, synthesized using recombinant DNA technology, that is entirely free from animal or human-derived components, thereby guaranteeing high purity and safety in both pharmaceutical and biomanufacturing contexts. As an example, in April 2025, InVitri Inc., a US-based provider specializing in animal-free recombinant proteins and excipients, introduced Optibumin 25. This product marks the first recombinant 25% human serum albumin specifically formulated for closed-system biomanufacturing. It has been optimized for various workflows including downstream processing, formulation, and cryopreservation, and is currently supplied in 100 mL single-use bags. Its chemically defined and animal-origin-free composition assures superior purity, consistency, and reduced risks of contamination. Furthermore, it is GMP-ready, capable of scaling to commercial production volumes, and delivers a stable, sterile solution that seamlessly integrates into critical applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.
Human Serum Albumin Market Leading Companies And Competitive Benchmarking
Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.
View The Full Human Serum Albumin Market Report:
Human Serum Albumin Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
